Skip to main
CRBU

Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences (CRBU) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Caribou Biosciences is poised for success, with the recent FDA's RMAT designation for their allogeneic BCMA-targeted CAR-T asset, CB-011, further mitigating regulatory risk and showcasing superior efficacy results compared to competitors. With upcoming catalysts, such as longer follow-up data from the ANTLER trial and initial dose expansion data for CB-011, there is strong potential for further positive developments and a successful path to market. As such, it is recommended to maintain a Buy rating and a 12-month price target of $9 per share.

Bears say

Caribou Biosciences is facing several challenges that contribute to a negative outlook, including the uncertainty and risk associated with developing and commercializing new therapies in the biopharmaceutical industry, potential competition from other companies in the CRISPR gene-editing space, and the company's historical lack of profitability. Additionally, the company's reliance on a single segment of business and its heavy dependence on the US market could limit its growth potential and make it vulnerable to fluctuations in the domestic market. Overall, these factors could significantly impact Caribou Biosciences' future financial performance and the success of its product candidates.

Caribou Biosciences (CRBU) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Caribou Biosciences (CRBU) Forecast

Analysts have given Caribou Biosciences (CRBU) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Caribou Biosciences (CRBU) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Caribou Biosciences (CRBU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.